Absci Stock News

Generative AI technology, like ChatGPT, is disrupting many industries including biopharma. For example, Absci is using AI to design & validate de novo antibodies.

Vancouver, Wash.

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

Absci Corp (NASDAQ: ABSI) shares are trading lower by 9.2% at $6.79 after the company reported fourth-quarter earnings results. Absci reported quarterly losses of 28 cents per share.

VANCOUVER, Wash., March 16, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a drug and target discovery company harnessing deep learning, AI and synthetic biology to expand the therapeuti

VANCOUVER, Wash., March 16, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a drug and target discovery company harnessing deep learning, AI and synthetic biology to expand the therapeutic

Absci (ABSI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Absci (ABSI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

VANCOUVER, Wash., March 01, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI ), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced that Sean McClain, CEO & Founder, will be participating on the Synthetic Biology Enabling Drug Discovery Panel at the Cowen 42 nd Annual Health Care Conference. The panel is scheduled to take place on March 8 th , 2022 at 12:30-1:30 p.m. Pacific Time / 3:30-4:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the company''s investor relations website at: investors.absci.com . About Absci Absci is … Full story available on Benzinga.com

VANCOUVER, Wash., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic

In the last trading session, 1.42 million shares of the Absci Corporation (NASDAQ:ABSI) were traded. Most recently the company’s share price was $8.83, and it changed around $0.05 or 0.57% from the last close, which brings the market valuation of the company to $799.73M. ABSI currently trades at a discount to its 52-week high of … Future Outlook And Stock Price Performance For Absci Corporation (NASDAQ: ABSI) Read More »

VANCOUVER, Wash., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeuti

VANCOUVER, Wash., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating virtually in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

The following slide deck was published by Absci Corporation in conjunction with this event.

Regulatory and other pipeline updates from Biogen (BIIB) and AMGN are among a few key highlights from the biotech sector during the past week.